Ritholtz Wealth Management Invests $245,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Ritholtz Wealth Management Invests $245,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Ritholtz Wealth Management bought a new position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Get Rating) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 871 shares of the pharmaceutical company's stock, valued at approximately $245,000.
根据Ritholtz Wealth Management在其最近提交给美国证券交易委员会(美国证券交易委员会)的文件中，该公司在第二季度购买了Vertex PharmPharmticals Inc.(VRTX-GET Rating)的新股票头寸。该机构投资者买入了这家制药公司871股股票，价值约245,000美元。
Several other hedge funds have also made changes to their positions in VRTX. IFM Investors Pty Ltd raised its holdings in Vertex Pharmaceuticals by 5.3% during the second quarter. IFM Investors Pty Ltd now owns 43,930 shares of the pharmaceutical company's stock worth $12,379,000 after purchasing an additional 2,199 shares in the last quarter. LVM Capital Management Ltd. MI raised its holdings in Vertex Pharmaceuticals by 10.2% during the second quarter. LVM Capital Management Ltd. MI now owns 36,500 shares of the pharmaceutical company's stock worth $10,285,000 after purchasing an additional 3,384 shares in the last quarter. BerganKDV Wealth Management LLC raised its holdings in Vertex Pharmaceuticals by 3.6% during the second quarter. BerganKDV Wealth Management LLC now owns 6,571 shares of the pharmaceutical company's stock worth $1,852,000 after purchasing an additional 229 shares in the last quarter. Private Advisor Group LLC raised its holdings in Vertex Pharmaceuticals by 7.3% during the second quarter. Private Advisor Group LLC now owns 31,771 shares of the pharmaceutical company's stock worth $8,953,000 after purchasing an additional 2,155 shares in the last quarter. Finally, Allworth Financial LP raised its holdings in Vertex Pharmaceuticals by 17.8% during the second quarter. Allworth Financial LP now owns 643 shares of the pharmaceutical company's stock worth $181,000 after purchasing an additional 97 shares in the last quarter. Institutional investors and hedge funds own 91.33% of the company's stock.
其他几家对冲基金也改变了它们在VRTX的头寸。IFM Investors Pty Ltd在第二季度将其在Vertex PharmPharmticals的持股增加了5.3%。IFM Investors Pty Ltd现在拥有43,930股这家制药公司的股票，价值12,379,000美元，此前在上个季度又购买了2,199股。LVM Capital Management Ltd.MI在第二季度将其在Vertex PharmPharmticals的持股增加了10.2%。LVM Capital Management Ltd.MI现在拥有36,500股这家制药公司的股票，价值10,285,000美元，上个季度又购买了3,384股。BerganKDV Wealth Management LLC在第二季度将其在Vertex PharmPharmticals的持股增加了3.6%。BerganKDV Wealth Management LLC在上个季度购买了229股后，现在拥有6571股这家制药公司的股票，价值1,852,000美元。Private Advisor Group LLC在第二季度将其在Vertex PharmPharmticals的持股增加了7.3%。Private Advisor Group LLC现在拥有这家制药公司31,771股股票，价值8,953,000美元，上个季度又购买了2,155股。最后，Allworth Financial LP在第二季度将其在Vertex PharmPharmticals的持股增加了17.8%。Allworth Financial LP现在拥有这家制药公司643股股票，价值18.1万美元，上个季度又购买了97股。机构投资者和对冲基金持有该公司91.33%的股票。
Analyst Upgrades and Downgrades
分析师升级和下调评级
Several research analysts recently issued reports on the stock. Morgan Stanley increased their price target on shares of Vertex Pharmaceuticals from $250.00 to $253.00 and gave the stock an "equal weight" rating in a report on Monday, August 8th. Cowen lifted their price target on shares of Vertex Pharmaceuticals from $305.00 to $310.00 and gave the company an "outperform" rating in a research report on Monday, June 13th. Barclays upped their price target on Vertex Pharmaceuticals from $291.00 to $307.00 and gave the stock an "overweight" rating in a report on Friday, August 5th. Maxim Group upgraded Vertex Pharmaceuticals from a "hold" rating to a "buy" rating and set a $325.00 target price on the stock in a research report on Wednesday, June 1st. Finally, Cowen raised their price target on Vertex Pharmaceuticals from $305.00 to $310.00 in a research report on Monday, June 13th. Six equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $291.65.
几位研究分析师最近发布了关于该股的报告。在8日周一的一份报告中，摩根士丹利将顶点制药的目标价从250.00美元上调至253.00美元，并给予该股“同等权重”的评级。考恩将Vertex PharmPharmticals的股票目标价从305.00美元上调至310.00美元，并在6月13日星期一的一份研究报告中给出了该公司“跑赢大盘”的评级。巴克莱将Vertex PharmPharmticals的目标价从291.00美元上调至307.00美元，并在周五的一份报告中给予该股“增持”评级。Maxim Group将Vertex PharmPharmticals的评级从持有上调至买入，并在6月1日周三的一份研究报告中为该股设定了325.00美元的目标价。最后，考恩在6月13日星期一的一份研究报告中将Vertex PharmPharmticals的目标价从305.00美元上调至310.00美元。6名股票研究分析师对该股的评级为持有，11名分析师给出了买入评级，一名分析师给出了该公司股票的强力买入评级。根据MarketBeat.com的数据，该股目前的平均评级为“适度买入”，共识目标价为291.65美元。
Vertex Pharmaceuticals Stock Up 2.9 %
Vertex制药类股上涨2.9%
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Rating) last released its earnings results on Thursday, August 4th. The pharmaceutical company reported $3.25 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.05 by $0.20. The firm had revenue of $2.20 billion during the quarter, compared to the consensus estimate of $2.13 billion. Vertex Pharmaceuticals had a net margin of 38.26% and a return on equity of 31.22%. Vertex Pharmaceuticals's revenue was up 22.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.80 earnings per share. On average, research analysts expect that Vertex Pharmaceuticals Incorporated will post 12.56 earnings per share for the current year.
顶点制药(纳斯达克：VRTX-GET评级)最近一次公布财报是在8月4日(星期四)。这家制药公司公布本季度每股收益(EPS)为3.25美元，超出分析师普遍预期的3.05美元，超出0.20美元。该公司本季度营收为22.亿美元，而市场普遍预期为21.3亿美元。Vertex PharmPharmticals的净利润率为38.26%，股本回报率为31.22%。与去年同期相比，Vertex PharmPharmticals的收入增长了22.5%。去年同期，该公司每股收益为2.80美元。研究分析师平均预计，Vertex制药公司本年度每股收益将达到12.56美元。
Insider Transactions at Vertex Pharmaceuticals
Vertex制药公司的内幕交易
In other Vertex Pharmaceuticals news, Chairman Jeffrey M. Leiden sold 132,079 shares of the business's stock in a transaction dated Monday, July 25th. The stock was sold at an average price of $281.38, for a total transaction of $37,164,389.02. Following the completion of the sale, the chairman now owns 2,423 shares of the company's stock, valued at $681,783.74. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Vertex Pharmaceuticals news, Chairman Jeffrey M. Leiden sold 132,079 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Monday, July 25th. The shares were sold at an average price of $281.38, for a total transaction of $37,164,389.02. Following the transaction, the chairman now directly owns 2,423 shares of the company's stock, valued at $681,783.74. The sale was disclosed in a filing with the SEC, which is available at this link. Also, SVP Joy Liu sold 3,747 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Monday, August 15th. The shares were sold at an average price of $303.90, for a total transaction of $1,138,713.30. Following the transaction, the senior vice president now directly owns 9,605 shares in the company, valued at $2,918,959.50. The disclosure for this sale can be found here. Insiders sold a total of 196,831 shares of company stock worth $56,532,979 in the last ninety days. Insiders own 0.40% of the company's stock.
在Vertex PharmPharmticals的其他消息中，董事长杰弗里·M·莱登在一笔日期为7月25日星期一的交易中出售了132,079股该公司股票。股票以281.38美元的平均价格出售，总成交金额为37,164,389.02美元。出售完成后，董事长现在拥有2423股公司股票，价值681,783.74美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，该文件可通过此超链接。在Vertex制药的其他消息方面，董事长杰弗里·M·莱登在7月25日星期一的一笔交易中出售了132,079股Vertex制药公司的股票。这些股票的平均价格为281.38美元，总成交金额为37,164,389.02美元。交易完成后，董事长现在直接持有2423股公司股票，价值681,783.74美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，该文件可在这个环节。此外，高级副总裁joy刘在8月15日星期一的一笔交易中出售了3,747股顶点制药的股票。这些股票以303.90美元的平均价格出售，总成交金额为1138,713.30美元。交易完成后，高级副总裁现在直接持有该公司9605股股份，价值2918,959.50美元。关于这次销售的披露可以找到这里。在过去的90天里，内部人士总共抛售了196,831股公司股票，价值56,532,979美元。内部人士持有该公司0.40%的股份。
About Vertex Pharmaceuticals
Vertex制药公司简介
(Get Rating)
(获取评级)
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation.
Vertex制药公司是一家生物技术公司，致力于开发治疗囊性纤维化的疗法并将其商业化。该公司销售SYMDEKO/SYMKEVI、Orkambi和Kalydeco，用于治疗囊性纤维化患者，这些患者的囊性纤维化跨膜传导调节基因具有特定突变；TRIKAFTA用于治疗至少有一种F508del突变的6岁或6岁以上的CF患者。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on Vertex Pharmaceuticals (VRTX)
- Defensive Stocks For A Volatile Market
- Will UPS Be Next to Deliver a Warning?
- SunPower Is Ready To Power Up Triple-Digit Earnings Gains
- Is This the Darkest Before the Dawn for Gap Stock?
- Build A Better Tech Portfolio With Jabil Inc.
- 免费获取StockNews.com关于Vertex PharmPharmticals的研究报告(VRTX)
- 防御性股票应对动荡的市场
- UPS会成为下一个发出警告的公司吗？
- SunPower准备推动三位数的收益增长
- 这是Gap Stock黎明前最黑暗的一次吗？
- 与捷普公司一起打造更好的技术产品组合。
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
接受Vertex制药日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Vertex制药和相关公司的最新新闻和分析师评级的每日简要摘要。